Long‐acting injectable cabotegravir for <scp>PrEP</scp> : A game‐changer in <scp>HIV</scp> prevention?

International audience; Background: Long-acting injectable cabotegravir (CAB-LA) represents a new additional option for HIV prevention in people at substantial risk of HIV infection that may fill the gaps in pre-exposure prophylaxis (PrEP) uptake, adherence, and retention in users having difficulty with oral PrEP.

Data from clinical trials demonstrated that CAB-LA was safe, highly effective, and wellaccepted for HIV prevention.

However, the occurrence of breakthrough HIV infections despite timely injections, HIV seroconversion timing and patterns, risk of selection and dissemination of resistance-associated mutations to integrase inhibitors, complexity of follow-up, logistical considerations, and its cost effectiveness compared with oral PrEP constitute significant issues for the integration of CAB-LA into clinical routine.

Findings: These concerns need to be addressed before moving forward with large-scale implementation programmes.

Pilot and implementation projects are required in the following areas: HIV testing algorithms, patient education, clinic procedures, protocols for switching and discontinuation, efficacy and safety in populations not included in clinical trials, and demedicalization processes.

The development of models to increase the uptake of, adherence to, and persistence with and after CAB-LA injections will also be of paramount importance for success.

Lessons learned from these projects will increase experience, staff expertise, and organizational and training capacities to support the roll-out of this new agent as part of HIV prevention programmes.

Conclusion: CAB-LA has not yet achieved its full potential in HIV prevention, and strong commitment from all stakeholders is required to push CAB-LA as a game-changer in HIV response.

K E Y W O R D S HIV pre-exposure prophylaxis, long-acting antiretroviral drugs